news
ACG 2024: J&J data reveals new Crohn’s treatment option
More patients given subcutaneous induction and maintenance treatment with Johnson & Johnson’s biologic obtained clinical remission at 48 weeks, compared to placebo, Phase III data showed.
List view / Grid view
Johnson and Johnson
article
Advancing targeted treatments for multiple myeloma
Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology, Johnson & Johnson Innovative Medicines, offers insight into the promising evidence of cell therapies and biologic-based treatments for patients with multiple myeloma.
news
Intravesical drug delivery system exhibits bladder cancer benefit
The drug delivery system provides local release of erdafitinib and may offer an alternative treatment for eligible bladder cancer patients with limited options.
news
J&J reveal long-term data for novel oral peptide
The new data suggests the IL-23 receptor antagonist peptide has potential to address the high unmet need of a durable and convenient oral option in moderate-to-severe plaque psoriasis.
news
Sanofi-Janssen collaboration to advance novel E. coli vaccine
A potential first-in-class extraintestinal pathogenic E. coli (ExPEC) vaccine set to be jointly developed by Sanofi and Janssen, could help to abate a pathogen that is key in driving global antimicrobial resistance (AMR).
news
Janssen rebrands its identity
Johnson & Johnson has updated the branding for its Janssen division, enabling its pharmaceutical and medtech segments to modernise and be more connected to its J&J brand.
news
Biopharma sees strong Q2 2023 market cap growth
Johnson & Johnson have been shifted from the top position in the market capitalisation ranking for the first time, due to Eli Lilly having the largest growth during Q2 2023, research shows.
